Regeneron Pharmaceuticals(us:REGN)
617.00
-2.72%
Updated on 2025-04-02
Open:630.51
Close:617.00
High:641.24
Low:615.00
Prev Close:634.23
Volume:1.06M
Turnover:660.13M
Turnover Ratio:0.97%
Shares:109.32M
MarketCap:67.45B
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 43 | 155304 | 0.14% | 6 | 14 | 13 |
| 2024-03-31 | 1346 | 91774631 | 83.26% | 138 | 461 | 525 |
| 2023-12-31 | 1294 | 91243887 | 83.39% | 169 | 436 | 498 |
| 2023-09-30 | 1221 | 90106015 | 82.80% | 109 | 390 | 509 |
| 2023-06-30 | 1222 | 91251734 | 83.78% | 84 | 381 | 556 |
| 2023-03-31 | 1224 | 97470200 | 88.83% | 126 | 425 | 488 |
| 2022-12-31 | 1192 | 93809288 | 85.59% | 164 | 328 | 521 |
| 2022-09-30 | 1126 | 91727206 | 84.31% | 106 | 357 | 489 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-06-30 | Fmr Llc | 10649474 | 9.66% | -144598 | -1.34% |
| 2024-06-30 | Vanguard Group Inc | 8993970 | 8.16% | 63729 | 0.71% |
| 2024-06-30 | Blackrock Inc. | 8446366 | 7.66% | -122288 | -1.43% |
| 2024-06-30 | Jpmorgan Chase & Co | 8277315 | 7.51% | 550141 | 7.12% |
| 2024-06-30 | State Street Corp | 4841127 | 4.39% | -421 | -0.01% |
| 2024-06-30 | Capital World Investors | 4638667 | 4.21% | -16188 | -0.35% |
| 2024-06-30 | Capital International Investors | 3134122 | 2.84% | 5112 | 0.16% |
| 2024-06-30 | Geode Capital Management, Llc | 2415350 | 2.19% | 38759 | 1.63% |
| 2024-06-30 | Dodge & Cox | 2315686 | 2.10% | -44178 | -1.87% |
| 2024-06-30 | Franklin Resources Inc | 1923102 | 1.74% | 228804 | 13.50% |
About
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Address:777 Old Saw Mill River Road
Website:http://www.regeneron.com
Market Movers